Ricevi le ultime notizie sulle azioni Galera Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di GRTX

Ultime notizie per

Galera Therapeutics

Galera Therapeutics Inc is a biopharmaceutical company that has been developing a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer, by reducing one of the most common side effects of radiotherapy, severe oral mucositis (SOM). Its product candidate, avasopasem, is for the reduction of SOM-induced radiotherapy. Galera advanced avasopasem through Phase 1, then conducted a 223-patient randomized Phase 2 (GT-201) clinical trial and a 455-patient Phase 3 (ROMAN) clinical trial. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

GALERA THERAPEUTICS INC by Galera Therapeutics, Inc.

Galera Therapeutics Inc

Comments

Galera Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO